Terminating coverage

ABGSC has ceased coverage of Nanexa due to the end of the contractual period. Our last published estimates are shown in this report.

Q1 report: work in progress

Q4 report: Update on NEX-22 Ph 1

Focus on NEX-22, Novo Nordisk and partner projects

New evaluation agreement in mAb space

Q3 report: NEX-22 on focus

Valuation update after the rights issue

SEK 75m from rights issue leads to project re-prioritisation. Primary focus on GLP-1 RA space (NEX-22 & Novo Nordisk collab.) New valuation range: SEK 1-6/share (SEK 2-5 prev.)

Takeaways from investor meeting

NEX-20 Ph 1 study completed

Update on capital raise

Rights issue of SEK 121m; subscription period: 12-26 Oct. Use of proceeds could finance operations well into '25. 67% dilution; new fair value range of SEK 2-5 (3-10).

Focusing on the right things

We provide a fresh look at Nanexa's prospects. GLP-1 receptor agonists a good space to focus efforts. Updated valuation with new fair value range of SEK 3-10.

Q2 report: advancing according to plan

Positive first human NEX-20 PK results

Q1 report